Voriconazole Tablet, Film Coated
NDC Package 65841-831-16

11-digit billing NDC: 65841083116

Package Information

Voriconazole tablets is known hypersensitivity to voriconazole or its excipients (4)Concomitant use with drugs that are highly dependent on CYP3A4 for metabolism, and for which elevated plasma concentrations are associated with serious and/or life-threatening reactions (4, 7)Concomitant use with drugs and herbal products that induce CYP2C19, CYP2C9, and/or CYP3A4 and for which significantly reduced voriconazole plasma concentrations may be associated with loss of efficacy (4, 7)Concomitant use of voriconazole is contraindicated with drugs that are highly dependent on CYP3A4 for metabolism, and for which elevated plasma concentrations are associated with serious and/or life-threatening reactions [see Drug Interactions (7)]:EplerenoneErgot alkaloids (e.g., ergotamine, dihydroergotamine)FinerenoneIvabradineLurasidoneNaloxegolPimozideQuinidineRifabutin [see Clinical Pharmacology (12.3)] Sirolimus [see Clinical Pharmacology (12.3)] TolvaptanVenetoclax: Coadministration at initiation and during the ramp-up phase is contraindicated in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) due to the potential for increased risk of tumor lysis syndrome [see Drug Interactions (7)].VoclosporinConcomitant use of voriconazole is contraindicated with drugs and herbal products that induce CYP2C19, CYP2C9, and/or CYP3A4 and for which significantly reduced voriconazole plasma concentrations may be associated with loss of efficacy [see Drug Interactions (7)]:CarbamazepineEfavirenz Concomitant use with efavirenz dosages of 400 mg every 24 hours or higher is contraindicated [see Clinical Pharmacology (12.3)].Long-acting barbituratesRifabutinRifampinRitonavir Concomitant use with high-dose ritonavir (400 mg every 12 hours) is contraindicated. This formulation utilizes a tablet, film coated delivery system. Marketed by Zydus Lifesciences Limited, this product is identified by NDC 65841-831 and is authorized under FDA application ANDA206747.

Identification & Billing

NDC Package Code
65841-831-16
Package Description
90 TABLET, FILM COATED in 1 BOTTLE
Product Code
11-Digit Billing Format
65841083116
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Voriconazole
Non-Proprietary Name
Voriconazole
Substance Name
Voriconazole
Dosage Form
Tablet, Film Coated - A solid dosage form that contains medicinal substances with or without suitable diluents and is coated with a thin layer of a water-insoluble or water-soluble polymer.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
Usage Information
Known hypersensitivity to voriconazole or its excipients (4)Concomitant use with drugs that are highly dependent on CYP3A4 for metabolism, and for which elevated plasma concentrations are associated with serious and/or life-threatening reactions (4, 7)Concomitant use with drugs and herbal products that induce CYP2C19, CYP2C9, and/or CYP3A4 and for which significantly reduced voriconazole plasma concentrations may be associated with loss of efficacy (4, 7)Concomitant use of voriconazole is contraindicated with drugs that are highly dependent on CYP3A4 for metabolism, and for which elevated plasma concentrations are associated with serious and/or life-threatening reactions [see Drug Interactions (7)]:EplerenoneErgot alkaloids (e.g., ergotamine, dihydroergotamine)FinerenoneIvabradineLurasidoneNaloxegolPimozideQuinidineRifabutin [see Clinical Pharmacology (12.3)] Sirolimus [see Clinical Pharmacology (12.3)] TolvaptanVenetoclax: Coadministration at initiation and during the ramp-up phase is contraindicated in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) due to the potential for increased risk of tumor lysis syndrome [see Drug Interactions (7)].VoclosporinConcomitant use of voriconazole is contraindicated with drugs and herbal products that induce CYP2C19, CYP2C9, and/or CYP3A4 and for which significantly reduced voriconazole plasma concentrations may be associated with loss of efficacy [see Drug Interactions (7)]:CarbamazepineEfavirenz Concomitant use with efavirenz dosages of 400 mg every 24 hours or higher is contraindicated [see Clinical Pharmacology (12.3)].Long-acting barbituratesRifabutinRifampinRitonavir Concomitant use with high-dose ritonavir (400 mg every 12 hours) is contraindicated. Concomitant use with low-dose ritonavir (100 mg every 12hours) should be avoided, unless an assessment of the benefit/risk to the patient justifies the use of voriconazole [see Clinical Pharmacology (12.3)]St. John's Wort [see Clinical Pharmacology (12.3)]

Regulatory & Marketing

Labeler Name
Zydus Lifesciences Limited
Product Type
Human Prescription Drug
FDA Application #
ANDA206747
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
05-25-2016
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (65841-831). Click a package code to view its specific billing and regulatory data.

100 TABLET, FILM COATED in 1 BOTTLE
500 TABLET, FILM COATED in 1 BOTTLE
30 TABLET, FILM COATED in 1 BOTTLE
1000 TABLET, FILM COATED in 1 BOTTLE
10 BLISTER PACK in 1 CARTON / 10 TABLET, FILM COATED in 1 BLISTER PACK (65841-831-30)

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 65841-831-16 identifies a specific commercial package of 90 tablet, film coated in 1 bottle of Voriconazole, a human prescription drug labeled by Zydus Lifesciences Limited. This tablet, film coated is formulated for oral use and contains voriconazole as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Zydus Lifesciences Limited on May 25, 2016. The current certification is valid through December 31, 2027.

How is this Zydus Lifesciences Limited product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 65841083116. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
65841-831-16
11-Digit CMS (5-4-2)
65841-0831-16

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.